NAT BIOMAED ENGINE:新方法为缺血提供潜在治疗方法

2017-07-06 佚名 生物通

陈教授与其临床合作伙伴C. Keith Ozaki医学博士、Joseph Woo医学博士共同开发了这款具有针对性的促新血管生长人工补丁。他们的研究发表于最新一期《Nature Biomedical Engineering》。

陈教授与其临床合作伙伴C. Keith Ozaki医学博士、Joseph Woo医学博士共同开发了这款具有针对性的促新血管生长人工补丁。他们的研究发表于最新一期《Nature Biomedical Engineering》。

“注射生长因子促进新血管生长是一种很有前途的缺血治疗实验方法,是较为流行的血管再生治疗手段,”陈教授说。“但在实践中,新生血管分支往往萌生成一个混乱曲折网络,像小毛球一般堵在那里,血液无法有效通过。我们想用人工干预手段使它们变得有序。”

陈和同事们设计了两个内皮细胞补丁,其中一个注入的细胞被预先组织成特定结构,另一个细胞没有任何组织结构,仅是简单地把细胞注入进去。体内实验结果显示,前者明显改善了缺血发生率,无秩序的后者则导致了血管“毛团”。

“该临床前研究提出了一个新方法以指导和增强血液向特定身体区域流动,”Ozaki说。“扩张后,血管为心脏和四肢等重要器官供应氧气等营养物资,治愈和保护功能性生命器官。”

3D打印容许尺度可以小到100微米,足够在毛细血管中施展。陈教授把它介绍给Innolign公司,3D打印技术的灵活性让Innolign和陈教授实验室的研究人员们迅速改进、测试设计,从而帮助他们识别良好的运作模式。此外,3D打印技术的可扩展性将帮助他们在更大、更复杂的生物体和组织环境中测试设计。

“我们努力想回答的问题是,植入物的结构是否对其功能具有重要影响,我们的实验结果证实了这一点,因此,巧妙地使用3D打印技术至关重要,”陈教授说。“补丁内部预制组织结构有助于引导新血管形成,使血管向下游组织输送足够血液,虽然不能完全恢复原有状态,我们仍观察到缺血组织功能性的恢复。”

陈教授指出,虽然该项目结果较为乐观,但仍处于早期研究阶段。展望未来,他们希望研究补丁的可伸缩性,尝试不同体系结构,看看是否有比目前这个更好的模式。

陈说:“这个项目已经持续很长世间了,临床合作伙伴对项目的成功不可或缺。作为生物工程师,我们主要关注的是如何构建补丁本身,而临床工作者的建议是设计关键,我们期待着与临床伙伴们的继续合作。”

原始出处:
Y. J. Woo, M. T. Yang & C. S. Chen.et al.3D-printed vascular networks direct therapeutic angiogenesis in ischaemia.Nature Biomedical Engineering

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1903242, encodeId=4d3a1903242d9, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Tue Feb 13 01:04:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917563, encodeId=f6ac191e563f3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Dec 12 19:04:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081382, encodeId=c076208138230, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Oct 15 20:04:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882268, encodeId=5eb918822686c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Jun 11 02:04:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785344, encodeId=57811e85344f7, content=<a href='/topic/show?id=0a9c6e87ef' target=_blank style='color:#2F92EE;'>#Engin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6787, encryptionId=0a9c6e87ef, topicName=Engin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Tue Nov 14 13:04:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399218, encodeId=632d139921839, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Sat Jul 08 07:04:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489827, encodeId=3675148982e3f, content=<a href='/topic/show?id=bcd5204ea9' target=_blank style='color:#2F92EE;'>#AED#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2047, encryptionId=bcd5204ea9, topicName=AED)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0108610571, createdName=makuansheng, createdTime=Sat Jul 08 07:04:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219210, encodeId=ece8219210e0, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Thu Jul 06 18:03:47 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1903242, encodeId=4d3a1903242d9, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Tue Feb 13 01:04:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917563, encodeId=f6ac191e563f3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Dec 12 19:04:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081382, encodeId=c076208138230, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Oct 15 20:04:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882268, encodeId=5eb918822686c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Jun 11 02:04:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785344, encodeId=57811e85344f7, content=<a href='/topic/show?id=0a9c6e87ef' target=_blank style='color:#2F92EE;'>#Engin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6787, encryptionId=0a9c6e87ef, topicName=Engin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Tue Nov 14 13:04:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399218, encodeId=632d139921839, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Sat Jul 08 07:04:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489827, encodeId=3675148982e3f, content=<a href='/topic/show?id=bcd5204ea9' target=_blank style='color:#2F92EE;'>#AED#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2047, encryptionId=bcd5204ea9, topicName=AED)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0108610571, createdName=makuansheng, createdTime=Sat Jul 08 07:04:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219210, encodeId=ece8219210e0, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Thu Jul 06 18:03:47 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
    2017-12-12 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1903242, encodeId=4d3a1903242d9, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Tue Feb 13 01:04:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917563, encodeId=f6ac191e563f3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Dec 12 19:04:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081382, encodeId=c076208138230, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Oct 15 20:04:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882268, encodeId=5eb918822686c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Jun 11 02:04:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785344, encodeId=57811e85344f7, content=<a href='/topic/show?id=0a9c6e87ef' target=_blank style='color:#2F92EE;'>#Engin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6787, encryptionId=0a9c6e87ef, topicName=Engin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Tue Nov 14 13:04:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399218, encodeId=632d139921839, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Sat Jul 08 07:04:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489827, encodeId=3675148982e3f, content=<a href='/topic/show?id=bcd5204ea9' target=_blank style='color:#2F92EE;'>#AED#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2047, encryptionId=bcd5204ea9, topicName=AED)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0108610571, createdName=makuansheng, createdTime=Sat Jul 08 07:04:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219210, encodeId=ece8219210e0, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Thu Jul 06 18:03:47 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
    2017-10-15 spoonycyy
  4. [GetPortalCommentsPageByObjectIdResponse(id=1903242, encodeId=4d3a1903242d9, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Tue Feb 13 01:04:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917563, encodeId=f6ac191e563f3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Dec 12 19:04:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081382, encodeId=c076208138230, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Oct 15 20:04:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882268, encodeId=5eb918822686c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Jun 11 02:04:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785344, encodeId=57811e85344f7, content=<a href='/topic/show?id=0a9c6e87ef' target=_blank style='color:#2F92EE;'>#Engin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6787, encryptionId=0a9c6e87ef, topicName=Engin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Tue Nov 14 13:04:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399218, encodeId=632d139921839, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Sat Jul 08 07:04:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489827, encodeId=3675148982e3f, content=<a href='/topic/show?id=bcd5204ea9' target=_blank style='color:#2F92EE;'>#AED#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2047, encryptionId=bcd5204ea9, topicName=AED)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0108610571, createdName=makuansheng, createdTime=Sat Jul 08 07:04:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219210, encodeId=ece8219210e0, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Thu Jul 06 18:03:47 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
    2018-06-11 liye789132251
  5. [GetPortalCommentsPageByObjectIdResponse(id=1903242, encodeId=4d3a1903242d9, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Tue Feb 13 01:04:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917563, encodeId=f6ac191e563f3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Dec 12 19:04:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081382, encodeId=c076208138230, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Oct 15 20:04:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882268, encodeId=5eb918822686c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Jun 11 02:04:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785344, encodeId=57811e85344f7, content=<a href='/topic/show?id=0a9c6e87ef' target=_blank style='color:#2F92EE;'>#Engin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6787, encryptionId=0a9c6e87ef, topicName=Engin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Tue Nov 14 13:04:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399218, encodeId=632d139921839, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Sat Jul 08 07:04:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489827, encodeId=3675148982e3f, content=<a href='/topic/show?id=bcd5204ea9' target=_blank style='color:#2F92EE;'>#AED#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2047, encryptionId=bcd5204ea9, topicName=AED)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0108610571, createdName=makuansheng, createdTime=Sat Jul 08 07:04:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219210, encodeId=ece8219210e0, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Thu Jul 06 18:03:47 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1903242, encodeId=4d3a1903242d9, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Tue Feb 13 01:04:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917563, encodeId=f6ac191e563f3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Dec 12 19:04:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081382, encodeId=c076208138230, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Oct 15 20:04:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882268, encodeId=5eb918822686c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Jun 11 02:04:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785344, encodeId=57811e85344f7, content=<a href='/topic/show?id=0a9c6e87ef' target=_blank style='color:#2F92EE;'>#Engin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6787, encryptionId=0a9c6e87ef, topicName=Engin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Tue Nov 14 13:04:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399218, encodeId=632d139921839, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Sat Jul 08 07:04:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489827, encodeId=3675148982e3f, content=<a href='/topic/show?id=bcd5204ea9' target=_blank style='color:#2F92EE;'>#AED#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2047, encryptionId=bcd5204ea9, topicName=AED)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0108610571, createdName=makuansheng, createdTime=Sat Jul 08 07:04:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219210, encodeId=ece8219210e0, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Thu Jul 06 18:03:47 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1903242, encodeId=4d3a1903242d9, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Tue Feb 13 01:04:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917563, encodeId=f6ac191e563f3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Dec 12 19:04:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081382, encodeId=c076208138230, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Oct 15 20:04:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882268, encodeId=5eb918822686c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Jun 11 02:04:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785344, encodeId=57811e85344f7, content=<a href='/topic/show?id=0a9c6e87ef' target=_blank style='color:#2F92EE;'>#Engin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6787, encryptionId=0a9c6e87ef, topicName=Engin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Tue Nov 14 13:04:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399218, encodeId=632d139921839, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Sat Jul 08 07:04:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489827, encodeId=3675148982e3f, content=<a href='/topic/show?id=bcd5204ea9' target=_blank style='color:#2F92EE;'>#AED#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2047, encryptionId=bcd5204ea9, topicName=AED)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0108610571, createdName=makuansheng, createdTime=Sat Jul 08 07:04:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219210, encodeId=ece8219210e0, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Thu Jul 06 18:03:47 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
    2017-07-08 makuansheng
  8. [GetPortalCommentsPageByObjectIdResponse(id=1903242, encodeId=4d3a1903242d9, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Tue Feb 13 01:04:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917563, encodeId=f6ac191e563f3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Dec 12 19:04:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081382, encodeId=c076208138230, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Oct 15 20:04:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882268, encodeId=5eb918822686c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Jun 11 02:04:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785344, encodeId=57811e85344f7, content=<a href='/topic/show?id=0a9c6e87ef' target=_blank style='color:#2F92EE;'>#Engin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6787, encryptionId=0a9c6e87ef, topicName=Engin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Tue Nov 14 13:04:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399218, encodeId=632d139921839, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Sat Jul 08 07:04:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489827, encodeId=3675148982e3f, content=<a href='/topic/show?id=bcd5204ea9' target=_blank style='color:#2F92EE;'>#AED#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2047, encryptionId=bcd5204ea9, topicName=AED)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0108610571, createdName=makuansheng, createdTime=Sat Jul 08 07:04:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219210, encodeId=ece8219210e0, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Thu Jul 06 18:03:47 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
    2017-07-06 dhzzm

    学习了分享了

    0

相关资讯

艾滋病复发病例激励研究人员探索新方法

两名原本被认为已经“痊愈”的艾滋病患者病情复发,给苦苦寻找艾滋病治疗方法的医学界泼了一盆冷水。不过,媒体1月2日报道,在不少艾滋病研究者看来,艾滋病“治愈”失败带来的不仅是失望,更多的是启示。为“飞跃”铺路美国波士顿布莱根妇女医院医生 Timothy Henrich 和 Daniel Kuritzkes 2013 年 7 月宣布,由他们主治的两名艾滋病患者在接受骨髓移植手术后,体内没有检测出艾滋病

Nature:救命!科学家发现生长造血干细胞的新方法

麦克马斯特大学干细胞和癌症研究所(McMaster University's Stem Cell and Cancer Research Institute)研究人员在理解人类血液系统干细胞方面取得了重大进步,他们发现了一种关键蛋白质如何允许这些细胞更好的控制和再生。 这项研究最新发表于《Nature》期刊,阐明了一种被称为Musashi-2的蛋白质如何调节重要造血干细胞的功能和发育。

捕捉小细胞肺癌有新方法

近日,复旦大学附属肿瘤医院检验科一项900多例的临床实践证实,通过体内一种血清新蛋白(ProGRP)的肿瘤标志物检测,可精确检测出小细胞肺癌。这意味着,只要“抽点血”、花60多元,便能在最快1个小时内给肺癌分类分型,对指导后续小细胞肺癌治疗方案的制订具有重大意义。该成果已发表在国际学术期刊《生物化学和生物物理研究通讯》上

Gut:治疗丙肝新方法

2016年4月21日讯/生物谷BIOON/--一项初步研究发现所有急性丙肝患者经过六周的短期直接抗病毒疗法治疗在随后的12周后检测不到丙肝病毒。研究者发起的研究证明sofosbuvir和ledipasvir两种药物在六周时间内就足以治疗急性丙肝病毒患者。 丙肝病毒感染者通常发展成急性丙型肝炎, 感染者通过自身可以清除10%到50%的病毒。丙肝病毒感染的早期诊断比较罕见,该病通常可能被忽视直

Nat Commun:一种诊断且治疗肺癌的新方法

近日,一项刊登于国际杂志Nature Communications上的研究报告中,来自新加坡的研究人员通过研究发现了一类名为oncomiRs的小RNA分子,其是引发肺癌发生的主要原因,相关研究或为理解肺癌对疗法产生耐药性的机制,以及有效监测并且开发治疗肺癌的新型疗法提供思路。文章中,研究者揭示了,肿瘤内罕见的癌症干细胞对常规疗法会产生耐受性,这就常常会引发肺癌患者疾病复发,由于oncomiRs分子

Nat Genet:识别癌症驱动因子的新方法

近日,一组研究人员开发出一种能查明癌症的基因“驱动程序”的新综合方法,新研究揭示了可能是治疗乳腺癌的八个可行靶标基因。 这项研究发表在Nature Genetics杂志上。研究人员研究了多种致癌途径,涉及正常细胞转变成癌细胞过程中的基因变异,其中包括控制癌细胞生长率的基因途径。细胞的高生长速率也被称为细胞增殖,被认为与乳癌患者不良预后有关。 分析多种类型基因组数据,研究人员能够确定在基因组